2022 AAPM 64th Annual Meeting
Back to session list

Session Title: Recent Task Group Reports on Brachytherapy: TG-222 and TG-303
Question 1: For mesh brachytherapy, the prescription point is defined as:
Reference:Reference: Wenzheng Feng, Mark Rivard, Elizabeth M. Carey, Robert A. Hearn, Sujatha Pai, Ravinder Nath, Yongbok Kim, Cynthia L. Thomason, Dale E. Boyce, Hualin Zhang. “Recommendations for intraoperative mesh brachytherapy: Report of AAPM Task Group No. 222”. Med Phys. 2021; 48(11): e969-e990.
Choice A:1 cm from the source plane
Choice B:0.5 cm from source plane
Choice C:2 cm from the source plane
Choice D:The target volume
Question 2: For a multi-source implant, what percentage of sources are required to be measured during source calibration?
Reference:Reference: Butler WM, Bice WS, DeWerd LA, et al. Third-party brachytherapy source calibrations and physicist responsibilities: report of the AAPM Low Energy Brachytherapy Source Calibration Working Group. Med Phys. 2008;35(9):3860-3865.
Choice A:5%
Choice B:10%
Choice C:50%
Choice D:100%
Question 3: Per the NRC, which of the following is considered as a medical event?
Reference:NRC 35.3045 https://www.nrc.gov/reading-rm/doc-collections/cfr/part035/part035-3045.html
Choice A:Total source strength administered differing by 20% or more from the total source strength documented in the post-implantation portion of the written directive.
Choice B:Sealed source(s) implanted directly into a location discontiguous from the treatment site, as documented in the post-implantation portion of the written directive.
Choice C:Total source strength administered outside of the treatment site exceeding 20% of the total source strength.
Choice D:Wrong radionuclide or a leaking sealed source resulting in a dose that exceeds 0.5 Sv (50 rem) to an organ or tissue.
Choice E:All of the above
Question 4: Increasing bandwidth reduces SNR, but may be necessary to
Reference:Liney GP, Moerland MA. Magnetic resonance imaging acquisition techniques for radiotherapy planning. Semin Radiat Oncol. 2014;24(3):160-168.
Choice A:Reduce SAR of the sequence
Choice B:Reduce chemical shift and susceptibility induced distortions
Choice C:Reduce the voxel size of the acquisition
Choice D:All of the above
Question 5: What are the advantages of a 3D over 2D sequence?
Reference:Ma J, Moerland MA, Venkatesan AM, et al. Pulse sequence considerations for simulation and postimplant dosimetry of prostate brachytherapy. Brachytherapy. 2017;16(4):743-753.
Choice A:Ability to acquire thinner slices
Choice B:Better in-plane resolution
Choice C:Less distortion along the slice direction
Choice D:A and B
Choice E:A and C
Question 6: Based on data analyzed in RetroEMBRACE, image guided adaptive brachytherapy combined with chemotherapy for cervix cancer:
Reference:Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 2016 Sep;120(3):428-433.
Choice A:led to little to no effect on local control
Choice B:led to poor local control with severe morbidity
Choice C:led to excellent local control with severe morbidity
Choice D:led to excellent local control with limited severe morbidity
Back to session list